

**ondine**



**For Immediate Release**

## **Ondine Highlights Successful Multi-Centre Gum Disease Trial Outcomes at Vancouver Symposium**

**Vancouver, Canada – May 29, 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company, today announced that it will be presenting clinical and scientific data on Periowave™ at a symposium being hosted by the Company on Thursday May 29, 2008 at the Morris J. Wosk Centre for Dialogue in Vancouver, B.C. Dr. Nicolas Loebel, the Company's Chief Technology Officer, will be presenting data on Photodisinfection, Periowave™ and results from the Canadian Multi-Centre Trial, a summary of which was initially released on May 7<sup>th</sup> 2008. Dr. Veronique Benhamou, DDS, Cert. Perio, a Periodontist and Director, Division of Periodontics, and Associate Professor at McGill University, Montreal Quebec, will be presenting case studies and discussing her clinical experiences with Periowave™ over the last two years.

In the Multi-Centre Trial,, Periowave™ treatment resulted in significantly increased clinical attachment level (CAL,  $p=0.003$ ) and reduced pocket depth (PD,  $p=0.01$ ) when compared to Scaling & Root Planing (SRP) alone. In addition, 53% more diseased sites demonstrated full resolution of clinical symptoms and converted to a healthy state (Clinical Attachment Level  $\leq 3\text{mm}$ ,  $p=0.0004$ ) than was found using SRP alone. These results demonstrate that Periowave™ photodisinfection therapy can provide significant clinical benefits in patients with chronic adult periodontitis.

“We are proud to present the details of the Canadian Multi-Centre trial to clinicians and industry participants at this upcoming symposium,” stated Carolyn Cross, President and CEO of Ondine Biopharma. “The multi-centre study represents the largest registered clinical trial of photodisinfection ever conducted, and we are pleased with the validation of these outcomes from the in-field experiences of clinicians such as Dr. Benhamou. These results provide further evidence that Periowave™ is an effective treatment modality for chronic periodontitis, a disease affecting over half of the adult population.”

### **About The Canadian Multi-Center Trial**

The Canadian Multi-Center Trial was a prospective, randomized, examiner-blinded study that included 121 patients and 4,500 defect treatment sites. Fifty-eight patients were included in the Periowave™ treatment arm and sixty-three patients were included in the control arm. The study was conducted at the University of Western Ontario, the University of Alberta, the University of Saskatchewan, and at a large private periodontal clinic in Toronto. More information about this trial can be found on the ClinicalTrials.gov website:

<http://clinicaltrials.gov/ct2/show/NCT00297531>

## **About Periowave™**

Periowave™ is a photodisinfection system commercialized by Ondine that utilizes low-intensity lasers and microbiological stains to target and destroy microbial pathogens and reduce the symptoms of disease. The photodisinfection technology was developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business plc, University College London. Periowave™ is currently approved in Canada and the European Union for several oral indications. Additional information about Periowave™ is available at [www.periowave.com](http://www.periowave.com)

## **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com).

## **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

## **FOR FURTHER INFORMATION please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
[ccross@ondinebiopharma.com](mailto:ccross@ondinebiopharma.com)

Christina Bessant  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 269  
[cbessant@equicomgroup.com](mailto:cbessant@equicomgroup.com)

Canaccord Adams Ltd  
Nominated Adviser &  
Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500